Alyaa R. Elsergany
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alyaa R. Elsergany has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ali Zaher
Faculty of Medicine, Helwan University, Cairo 11813, Egypt
1 shared publication - Khalid Atallah
Surgical Oncology Department, Oncology Center, Mansoura University, Al Mansurah, Egypt
1 shared publication - Mostafa Abdelhakiem
Associate professor of Medical Oncology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication Omar Ahmed Abualata
1-Mansoura Manchester Medical Program, Faculty of Medicine, Mansoura University, Mansoura, Egyp
1 shared publication- Omar Hamdy
Surgical Oncology Department, Oncology Center, Mansoura University, Mansoura 35516, Egypt
1 shared publication - Rana Abdo
Mansoura University Hospitals, Mansoura 35516, Egypt
1 shared publication
Latest Publications
- Open Access
Omission of Axillary Surgery After Neoadjuvant Therapy in Her2-Positive Breast Cancer: Who Are the Candidates?
Background: This study aimed to evaluate the lymph node (LN) response in Her2-positive breast cancer patients who received neoadjuvant therapy (NAT) and to discuss if axillary staging can be omitted in these patients. Methods: This is a retrospective cohort study including patients with Her2+ breast cancer at our center from March 2022 to September 2023. Results: The study included 139 patients in the final analysis; 69.1% of the patients had HR+/Her2+ disease while 30.9% had HR−/Her2+ disease. Most of the included patients (129 patients = 92.8%) had initially node-positive or suspicious disease. A total of 112 patients (80.6%) showed clinically negative axillary LNs (cN0) after NAT. All of them showed pathologically node-negative disease. When comparing the pathological node-positive vs. -negative groups, the following was found to be statistically significant: degree of Her2 positivity, number of anti-Her2 cycles, pre- and post-neoadjuvant LN status, and primary tumor radiological and pathological response. Also, all T1 tumors before NAT showed negative LNs after NAT, but it was statistically non-significant. Conclusions: Axillary staging may be omitted in Her2+ patients with cN0 after NAT, especially those with early tumors, strong Her2+ disease, cN0 before NAT, and those in whom the primary tumor achieved a complete clinical response.
Open AccessOmission of Axillary Surgery After Neoadjuvant Therapy in Her2-Positive Breast Cancer: Who Are the Candidates?
Background: This study aimed to evaluate the lymph node (LN) response in Her2-positive breast cancer patients who received neoadjuvant therapy (NAT) and to discuss if axillary staging can be omitted in these patients. Methods: This is a retrospective cohort study including patients with Her2+ breast cancer at our center from March 2022 to September 2023. Results: The study included 139 patients in the final analysis; 69.1% of the patients had HR+/Her2+ disease while 30.9% had HR−/Her2+ disease. Most of the included patients (129 patients = 92.8%) had initially node-positive or suspicious disease. A total of 112 patients (80.6%) showed clinically negative axillary LNs (cN0) after NAT. All of them showed pathologically node-negative disease. When comparing the pathological node-positive vs. -negative groups, the following was found to be statistically significant: degree of Her2 positivity, number of anti-Her2 cycles, pre- and post-neoadjuvant LN status, and primary tumor radiological and pathological response. Also, all T1 tumors before NAT showed negative LNs after NAT, but it was statistically non-significant. Conclusions: Axillary staging may be omitted in Her2+ patients with cN0 after NAT, especially those with early tumors, strong Her2+ disease, cN0 before NAT, and those in whom the primary tumor achieved a complete clinical response.
- Open Access
- 1 March 2023
- Published by Egyptian Knowledge Bank in International Journal of Cancer and Biomedical Research
- Vol. 7 (1) , 1-11
CRISPR-Cas9: what is beyond cancer immunotherapy?
Background: Cancer immunotherapy has generated several breakthroughs in targeted therapy; it has been vital for understanding and treating many previously treatment-resistant cancer patients as human papilloma virus (HPV) vaccination and genetic editing of the individual’s immune cells in what is known as adoptive cell transfer (ACT). CRISPR/Cas9 discovery has been ground breaking in the gene-editing industry given its simplicity and ability to genetically edit several genes simultaneously. Current application of autologous chimerically activated receptors (CAR) T cells has proven to be beneficial for several leukemia and multiple myeloma patients but faces several obstacles and limitations. Purpose: In this article, we explore several approaches by which CRISPR/Cas 9 can edit immune cells to generate more diverse and broad application of adoptive cell transfer. Summary of the findings CRISPR/Cas9 could potentially generate allogenic CAR-T cells through knocking out TCR and human leucocytic antigen (HLA) molecules on the transfused immune cells thereby preventing graft vs host disease (GVHD) and rejection, respectively. Moreover, CRISPR/Cas9 can generate safe CAR-T cells by preventing cytokine release storm (CRS). Conclusion Combining these two revolutionary concepts, CRISPR/Cas9 and immunotherapy, can allow us to more broadly apply immunotherapy and deliver it to more cancer patients. There are several proposed advantages and implications of using CRISPR/Cas 9 as a gene editing tool to produce “off the shelf” immune cells that are both effective and safe
- 1 March 2023
- Published by Egyptian Knowledge Bank in International Journal of Cancer and Biomedical Research
- Vol. 7 (1) , 1-11
Open AccessCRISPR-Cas9: what is beyond cancer immunotherapy?
Background: Cancer immunotherapy has generated several breakthroughs in targeted therapy; it has been vital for understanding and treating many previously treatment-resistant cancer patients as human papilloma virus (HPV) vaccination and genetic editing of the individual’s immune cells in what is known as adoptive cell transfer (ACT). CRISPR/Cas9 discovery has been ground breaking in the gene-editing industry given its simplicity and ability to genetically edit several genes simultaneously. Current application of autologous chimerically activated receptors (CAR) T cells has proven to be beneficial for several leukemia and multiple myeloma patients but faces several obstacles and limitations. Purpose: In this article, we explore several approaches by which CRISPR/Cas 9 can edit immune cells to generate more diverse and broad application of adoptive cell transfer. Summary of the findings CRISPR/Cas9 could potentially generate allogenic CAR-T cells through knocking out TCR and human leucocytic antigen (HLA) molecules on the transfused immune cells thereby preventing graft vs host disease (GVHD) and rejection, respectively. Moreover, CRISPR/Cas9 can generate safe CAR-T cells by preventing cytokine release storm (CRS). Conclusion Combining these two revolutionary concepts, CRISPR/Cas9 and immunotherapy, can allow us to more broadly apply immunotherapy and deliver it to more cancer patients. There are several proposed advantages and implications of using CRISPR/Cas 9 as a gene editing tool to produce “off the shelf” immune cells that are both effective and safe